84 related articles for article (PubMed ID: 8539919)
1. Beneficial metabolic impact of the novel immunosuppressant rapamycin in chronic canine islet autograft recipients.
Kneteman NM; Lakey JR; Wagner T; Finegood D
Transplant Proc; 1995 Dec; 27(6):3213. PubMed ID: 8539919
[No Abstract] [Full Text] [Related]
2. Impact of antipassenger lymphocyte globulin on functional graft survival of discordant xenoislet grafts from a large animal donor.
Troppmann C; Papalois BE; Gruessner AC; Moon C; Matas AJ; Nakhleh RE; Gruessner RW
Transplant Proc; 1996 Apr; 28(2):842-4. PubMed ID: 8623429
[No Abstract] [Full Text] [Related]
3. Effect of rapamycin on islet and skin xenograft survival.
Bobbio SA; Porter JG; Monaco AP
Transplant Proc; 1993 Aug; 25(4):2745-6. PubMed ID: 8356733
[No Abstract] [Full Text] [Related]
4. FK 506 versus cyclosporine A for steroid-free synergistic combination therapy with rapamycin in a discordant large animal donor xenoislet transplant model.
Troppmann C; Papalois BE; Gruessner AC; Nakhleh RE; Gruessner RW
Transplant Proc; 1997; 29(1-2):914-5. PubMed ID: 9123585
[No Abstract] [Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Johnson EM; Zimmerman J; Duderstadt K; Chambers J; Sorenson AL; Granger DK; Almond PS; Fryer Jp; Leventhal JR; Scarola J; Matas AJ; Canafax DM
Transplant Proc; 1996 Apr; 28(2):987. PubMed ID: 8623490
[No Abstract] [Full Text] [Related]
6. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients.
Kneteman NM; Lakey JR; Wagner T; Finegood D
Transplantation; 1996 Apr; 61(8):1206-10. PubMed ID: 8610419
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Brattström C; Tydén G; Säwe J; Herlenius G; Claesson K; Groth CG
Transplant Proc; 1996 Apr; 28(2):985-6. PubMed ID: 8623489
[No Abstract] [Full Text] [Related]
8. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model.
Hirshberg B; Preston EH; Xu H; Tal MG; Neeman Z; Bunnell D; Soleimanpour S; Hale DA; Kirk AD; Harlan DM
Transplantation; 2003 Jul; 76(1):55-60. PubMed ID: 12865786
[TBL] [Abstract][Full Text] [Related]
9. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model.
Granger DK; Cromwell JW; Canafax DM; Matas AJ
Transplant Proc; 1996 Apr; 28(2):984. PubMed ID: 8623488
[No Abstract] [Full Text] [Related]
10. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related.
Yakimets WJ; Lakey JR; Yatscoff RW; Katyal D; Ao Z; Finegood DT; Rajotte RV; Kneteman NM
Transplantation; 1993 Dec; 56(6):1293-8. PubMed ID: 8278991
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression for pancreatic islet transplantation.
Berney T; Buhler LH; Majno P; Mentha G; Morel P
Transplant Proc; 2004 Mar; 36(2 Suppl):362S-366S. PubMed ID: 15041369
[TBL] [Abstract][Full Text] [Related]
12. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy.
Cohen DS; Fisher RA; Shapiro JH; Goggins WC; Tawes JW; Mills S; Contos M; Ham JM; Schroeder TJ
Transplant Proc; 1996 Oct; 28(5):2501-5. PubMed ID: 8907923
[No Abstract] [Full Text] [Related]
13. Sirolimus in transplantation.
Stepkowski SM; Tian L; Wang ME; Qu X; Napoli K; Kahan BD
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):383-90. PubMed ID: 9437494
[TBL] [Abstract][Full Text] [Related]
14. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts.
Shapiro AM; Geng Hao E; Lakey JR; Finegood DT; Rajotte RV; Kneteman NM
Transplantation; 2002 Dec; 74(11):1522-8. PubMed ID: 12490784
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity of immunosuppressive drugs.
Bennett WM; Burdmann E; Andoh T; Elzinga L; Franceschini N
Miner Electrolyte Metab; 1994; 20(4):214-20. PubMed ID: 7531274
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection.
Wennberg L; Wallgren AC; Sundberg B; Rafael E; Zhu S; Liu J; Tibell A; Karlsson-Parra A; Groth CG; Korsgren O
Transplant Proc; 1995 Dec; 27(6):3314-5. PubMed ID: 8539967
[No Abstract] [Full Text] [Related]
17. Sirolimus: a new agent for clinical renal transplantation.
Kahan BD
Transplant Proc; 1997; 29(1-2):48-50. PubMed ID: 9123092
[No Abstract] [Full Text] [Related]
18. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.
Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
Transplant Proc; 2005 Mar; 37(2):1326-7. PubMed ID: 15848711
[TBL] [Abstract][Full Text] [Related]
19. Decreased chronic failure of intraperitoneal impure islets versus intrahepatic pure islets in a canine autograft model.
Wahoff DC; Nelson LA; Papalois BE; Curtis DA; Gores PF; Sutherland DE
Transplant Proc; 1995 Dec; 27(6):3186. PubMed ID: 8539902
[No Abstract] [Full Text] [Related]
20. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
Lin Y; Waer M
Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
